Prognostic impact of treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the acute phase and medium-term on COVID-19 infected patients.

27 August 2021 (08:00 - 20:00)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Miss Carolina Broco

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

57 More presentations in this session

Presentation thumbnail

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Doctor J. Borovac (Split, HR)

Abstract Slides

Presentation thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Doctor A. KANWAL (Valhalla, US)

Abstract Slides

Presentation thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Doctor K. Dzaurova (Moscow, RU)

Abstract Slides

Presentation thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Presentation thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Mrs A. Boulmpou (Nijmegen, NL)

Abstract Slides

Access the full session

Session thumbnail

Pharmacology and pharmacotherapy e-posters

The Event

ESC Congress 2021 - The Digital Experience

27 August 2021 08:00 CET

You may be interested in

Congress Session

Novel drug therapies in hypertension: new kids on the block

Congress Presentation

Bradycardic effect of endothelial-specific bradykinin type-II receptors overexpression in mice: impact on blood pressure.

Congress Presentation

RNA therapeutics for treatment of hypertension